Helsinn initiates two new global Phase III studies with anamorelin
07 mars 2019 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn initiates two new global Phase III studies with anamorelin Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung...